Chimeric Therapeutics Share Price and Company Fundamentals



Price
$0.335
Change
0.000 (0.000%)
52 week
0.24 - 0.44

Last traded: Yesterday at 6:10 AM

Chimeric Therapeutics Limited researches, develops, and commercializes cell therapies for cancer in Australia. The company develops CLTX CAR T cell therapy that is Phase I clinical study in Glioblastoma; and CHM 2101, which is in preclinical study for neuroendocrine tumours, colorectal, pancreatic, and gastric cancer. It has a strategic partnership with OncoBay Clinical for the development program of CLTX CAR T. The company was incorporated in 2020 and is based in Carlton, Australia.

Key Metrics

PE ratio

-

PB ratio

4.09

Dividend yield

Beta

-

Market cap

$111.7M

Enterprise value

$80.68M

Company profile

Primary activitiesChimeric is a biotechnology company developing a cancer cell therapy drug
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.chimerictherapeutics.com
Mailing address62 Lygon Street Level 3 Carlton South Carlton VIC 3053 Australia
Phone / Fax61 3 9824 5254 /
Share registryBOARDROOM PTY LIMITED

Dividends

Chimeric Therapeutics does not pay dividends.

Company Executives

As of Sep 2021, following are the company executives and directors listed on Chimeric Therapeutics.

NameTitleAgeTotal Pay
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDExec. Chairman64
Ms. Jennifer ChowCEO, COO, MD & Director
Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBADirector & Sec.59

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

0.00%

Return on assets

-50.84%

Return on equity

-120.59%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Chimeric Therapeutics is 111.7M and its enterprise value is 80.68M.

Companies similar to Chimeric Therapeutics (CHM)

Chimeric Therapeutics (ASX:CHM) Frequently Asked Questions

1. What is Chimeric Therapeutics's Stock Symbol?

Chimeric Therapeutics trades on ASX under the ticker symbol "CHM".

2. What is Chimeric Therapeutics's stock price today?

One share of CHM stock can currently be purchased for approximately $0.335.

3. How can I contact Chimeric Therapeutics?

Chimeric Therapeutics's mailing address is 62 Lygon Street Level 3 Carlton South Carlton VIC 3053 Australia. The company can be reached via phone at 61 3 9824 5254.

4. What is Chimeric Therapeutics's official website?

The official website of Chimeric Therapeutics is http://www.chimerictherapeutics.com.

5. Which share registry manages Chimeric Therapeutics's stock?

Chimeric Therapeutics's stock is managed by BOARDROOM PTY LIMITED.